Premium
Hybrid nanoreservoirs based on dextran‐capped dendritic mesoporous silica nanoparticles for CD133‐targeted drug delivery
Author(s) -
Zahiri Mahsa,
Babaei Maryam,
Abnous Khalil,
Taghdisi Seyed Mohammad,
Ramezani Mohammad,
Alibolandi Mona
Publication year - 2020
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.29019
Subject(s) - dextran , mesoporous silica , drug delivery , nanoparticle , targeted drug delivery , drug , mesoporous material , nanotechnology , chemical engineering , chemistry , materials science , chromatography , pharmacology , organic chemistry , catalysis , medicine , engineering
In this study, the chemical features of dendritic mesoporous silica nanoparticles (DMSNs) provided the opportunity to design a nanostructure with the capability to intelligently transport the payload to the tumor cells. In this regard, doxorubicin (DOX)‐encapsulated DMSNs was electrostatically surface‐coated with polycarboxylic acid dextran (PCAD) to provide biocompatible dextran‐capped DMSNs (PCAD‐DMSN@DOX) with controlled pH‐dependent drug release. Moreover, a RNA aptamer against a cancer stem cell (CSC) marker, CD133 was covalently attached to the carboxyl groups of DEX to produce a CD133‐PCAD‐DMSN@DOX. Then, the fabricated nanosystem was utilized to efficiently deliver DOX to CD133+ colorectal cancer cells (HT29). The in vitro evaluation in terms of cellular uptake and cytotoxicity demonstrated that the CD133‐PCAD‐DMSN@DOX specifically targets HT29 as a CD133 overexpressed cancer cells confirmed by flow cytometry and 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2‐ H ‐tetrazolium bromide assay. The potentially promising intelligent‐targeted platform suggests that targeted dextran‐capped DMSNs may find impressive application in cancer therapy.